Abstract
This document is specifically addressed to pharmaceutical manufacturers and medicinal drug regulatory authorities who share the responsibility for ensuring the safe use of medicinal drugs by patients who operate motor vehicles. The material presented is expected to lead to guidelines for standardized assessment of each new medicinal drug's hazard potential for driving as part of the registration process.